EMA: ABEL for HVD(P)s, PK metrics [Regulatives / Guidelines]

posted by Pharma_88 – India, 2020-09-08 11:05 (923 d 23:16 ago) – Posting: # 21910
Views: 6,029

Thanks For your detailed response.

I have a few questions and need your suggestion in this regards.

I have kept following parameters in SS study (IR VS ER).

Primary pharmacokinetic parameters: AUC0-τ,ss
Secondary pharmacokinetic parameters:
Day 01 to 04-Morning dose: Cpd
Day 04 (Morning dose): Cτ,ss, Cmax,ss, Cmin,ss, Tmax,ss, accumulation index, %Fluctuation and Cav

Please correct me.

and also want to know for Cpd and Cτ,ss:

Cpd: All pre-dose samples needs to be considered including profiling day sample or only samples before profiling day?

Cτ,ss: How to calculate it? Whether morning dose of Day 04 is also need to be taken in to account to calculate.

Thanks.

Complete thread:

UA Flag
Activity
 Admin contact
22,546 posts in 4,721 threads, 1,608 registered users;
22 visitors (0 registered, 22 guests [including 6 identified bots]).
Forum time: 09:21 CET (Europe/Vienna)

Science is the great antidote to the poison
of enthusiasm and superstition.    Adam Smith

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5